
Sign up to save your podcasts
Or


Dr. Ashwin Singh Parihar speaks with Dr. Phillip Kuo, Dr. Andrew Armstrong, and Dr. Ken Herrmann about how 68Ga-PSMA-11 PET can predict response of metastatic prostate cancer following 177Lu-PSMA-617 therapy. The VISION Trial.
Quantitative 68Ga-PSMA-11 PET and ClinicalOutcomes in Metastatic Castration-resistant ProstateCancer Following 177Lu-PSMA-617 (VISION Trial). Kuo and Morris et al. Radiology 2024; 312(2):e233460.
By The Radiological Society of North America4.7
8787 ratings
Dr. Ashwin Singh Parihar speaks with Dr. Phillip Kuo, Dr. Andrew Armstrong, and Dr. Ken Herrmann about how 68Ga-PSMA-11 PET can predict response of metastatic prostate cancer following 177Lu-PSMA-617 therapy. The VISION Trial.
Quantitative 68Ga-PSMA-11 PET and ClinicalOutcomes in Metastatic Castration-resistant ProstateCancer Following 177Lu-PSMA-617 (VISION Trial). Kuo and Morris et al. Radiology 2024; 312(2):e233460.

4,359 Listeners

498 Listeners

28 Listeners

76 Listeners

2,435 Listeners

30 Listeners

8,233 Listeners

460 Listeners

613 Listeners

45 Listeners

204 Listeners

9,829 Listeners

1,616 Listeners

58 Listeners

41 Listeners